Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

Antinori, Andrea; Ammassari, Adriana; Torti, Carlo; Marconi, Patrizia; Andreoni, Massimo; Angarano, Gioacchino; Bonora, Stefano; Castagna, Antonella; Cauda, Roberto; Clerici, Mario; Monforte, Antonella d’Arminio; Luca, Andrea De; Perri, G. Di; Galli, Massimo; Girardi, Enrico; Gori, Andrea; Lazzarin, Adriano; Caputo, Sergio Lo; Mazzotta, Francesco; Montella, Francesco; Mussini, Cristina; Perno, Carlo Federico; Puoti, Massimo; Rizzardini, Giuliano; Rusconi, Stefano; Vullo, Vincenzo; Carosi, G.

doi:10.1007/s15010-008-8134-8

Cited by 7 publications

(3 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, HIV-infected patients are affected to a greater extent by diseases (e.g., diabetes, malignancies) indicative of a praecox ageing process. These data are in accordance with those reported by other authors and emphasize the need for additional therapeutic measures to further decrease the incidence of mortality in this population [23,24].…”

Section: Discussionsupporting

confidence: 93%

Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In individuals with progressed HIV infections, even if the TST is negative, repeat tests are recommended once the CD4+ T cell count recovers to at least 400/mm 3 [4]. As TST is influenced by decreased cellular immunity in patients with AIDS, chest radiography is required regardless of the TST results if patients present with respiratory symptoms; moreover, sputum acid-fast bacilli staining and a tuberculosis culture should be conducted [12]. Serologic tests for hepatitis A virus, hepatitis B virus (HBV), and HCV and screening tests for syphilis, toxoplasmosis, gonorrhea and other sexually transmitted diseases should be performed [1314151617].…”

Section: Initial Evaluation and Follow-up Testsmentioning

confidence: 99%

The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans

et al. 2019

View full text Add to dashboard Cite

Since the establishment of the Committee for Clinical Guidelines for the Diagnosis and Treatment of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) by the Korean Society for AIDS in 2010, clinical guidelines have been prepared in 2011, 2013, and 2015. As new research findings on the epidemiology, diagnosis, and treatment of AIDS have been published in and outside of Korea along with the development and introduction of new antiretroviral medications, a need has arisen to revise the clinical guidelines by analyzing such new data. The clinical guidelines address the initial evaluation of patients diagnosed with HIV/AIDS, follow-up tests, appropriate timing of medication, appropriate antiretroviral medications, treatment strategies for patients who have concurrent infections with hepatitis B or C virus, and treatment in pregnant women. Through these clinical guidelines, the Korean Society for AIDS and the Committee for Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS would like to contribute to overcoming AIDS by delivering the latest data and treatment strategies to healthcare professionals who treat AIDS in the clinic.

show abstract

“…All patients who present late with HIV infection (with CD4 + T-cell counts <350 cells/µl) should have their HIV disease status and comorbidities evaluated promptly, and an individual treatment plan should be developed that encompasses both antiretroviral therapy (ART) and, where necessary, treatment for opportunistic diseases [2]. Current guidelines for resource-rich settings recommend that all patients who present with a CD4 + T-cell count <350 cells/µl should receive treatment and that treatment should be considered for some patients who present above this threshold but with other indicators [3][4][5][6][7].…”

Section: When Should Treatment Be Started?mentioning

confidence: 99%

Management of Late-presenting Patients with HIV Infection

et al. 2010

View full text Add to dashboard Cite

Managing patients who present late with HIV infection is challenging. All late-presenting patients should have an individual treatment plan that encompasses both antiretroviral therapy and, where necessary, treatment for opportunistic diseases. Timely initiation of treatment in late presenters is crucial but the optimal time to start therapy depends on many individual factors, including the presence of opportunistic infection and potential drug-drug interactions. Primary drug resistance is an important contributor to poor clinical outcomes in HIV; resistance profiling before treatment initiation is therefore recommended. The choice of initial HIV treatment should reflect patient characteristics, the results of resistance testing and the complexity of concomitant disease.

show abstract

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

Abstract: Background: Individuals with

Cited by 7 publications

References 64 publications

Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort

Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort

The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans

Management of Late-presenting Patients with HIV Infection

Contact Info

Product

Resources

About